

Accelerating Innovation to Impact: Learning from Triple-Drug Therapy for Lymphatic Filariasis and Other Innovations

Guest Editor: Eric Ottesen

CONTENTS

The Role of Innovation in Delivering the 2021–2030 Neglected Tropical Disease Road Map Mwelecele Ntuli Malecela	1	Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned Bhupendra Tripathi, Nupur Roy, and Neeraj Dhingra	29
Foreword: Towards Accelerating Tool Development for Global Health Eric A. Ottesen	2	The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific Merelesita Rainima-Qaniuci, Hansell Blanche Lepaitai, Rasul Bhagirov, Eswara Padmasiri, Take Naseri, Robert Thomsen, Kimberly Y. Won, Tara A. Brant, Emily Dodd, Motusa Tuileama Nua, Fara Utu, Aifili Tufa, Emi Chutaro, Janet Camacho, Lynette Suaunoa-Scanlan, Li Jun Thean, Jyotishna Mani, Myra Hardy, Josaia Samuela, Lucia Romani, John Kaldor, Andrew C. Steer, Daniel Faktaufon, Vinaisi Bechu, Flora Naqio, Vine Sosene, Makoto Sekihara, Junko Otaki, Tamara S. Buhagiar, and Aya Yajima	39
Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis Julie Jacobson	4	Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin–Diethylcarbamazine–Albendazole for Lymphatic Filariasis Elimination Raj Shankar Ghosh, Pradeep Haldar, and Julie Jacobson	48
Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis Gary J. Weil, Peter U. Fischer, and Alison Krentel	13	Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis Anastasia Pantelias, Jonathan D. King, Patrick Lammie, and Gary J. Weil	56
Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis Purushothaman Jambulingam, Swaminathan Subramanian, Kaliannagounder Krishnamoorthy, Taniawati Supali, Peter Fischer, Christine Dubray, Carl Fayette, Jean Frantz Lemoine, Moses Laman, Christopher King, Josaia Samuela, Myra Hardy, and Gary J. Weil	18	Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program Olaf Valverde Mordt, Antoine Tarral, and Nathalie Strub-Wourgaft	61
Accelerating the Uptake of WHO Recommendations for Mass Drug Administration Using Ivermectin, Diethylcarbamazine, and Albendazole Jonathan D. King, Julie Jacobson, and Alison Krentel	26	Reflections on “Orchestrating for Impact”: Harmonizing across Stakeholders to Accelerate Global Health Gains Julie Jacobson and Alan Brooks	67

For more information about the American Society of Tropical Medicine and Hygiene please visit us at www.astmh.org

The American Journal of Tropical Medicine and Hygiene is online at www.ajtmh.org